VYNE Therapeutics Inc. Common Stock (VYNE)

Price$0.66

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)62.31%

Price vs S&P 500 (4W)-0.67%

VGM Score35.89

Market Capitalization$21.88M

All Metrics

Book Value / Share (Quarterly)$0.74

P/TBV (Annual)1.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.90%

Cash Flow / Share (Quarterly)$-0.77

Price vs S&P 500 (YTD)4.94%

Gross Margin (TTM)81.03%

Net Profit Margin (TTM)-4726.21%

EPS (TTM)$-0.50

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-0.50

Revenue Growth (5Y)-51.38%

EPS (Annual)$-0.62

ROI (Annual)-95.38%

Gross Margin (Annual)93.38%

Net Profit Margin (5Y Avg)-6405.56%

Cash / Share (Quarterly)$0.74

Revenue Growth QoQ (YoY)-57.43%

ROA (Last FY)-87.81%

Revenue Growth TTM (YoY)-24.96%

EBITD / Share (TTM)$-0.57

ROE (5Y Avg)-85.74%

Operating Margin (TTM)-5367.62%

Cash Flow / Share (Annual)$-0.99

P/B Ratio0.89x

P/B Ratio (Quarterly)0.81x

Net Income / Employee (Annual)$-2,648,300

EV / Revenue (TTM)-6.06x

Net Interest Coverage (TTM)-6.96x

ROA (TTM)-62.70%

EPS Incl Extra (Annual)$-0.62

Current Ratio (Annual)12.53x

Quick Ratio (Quarterly)20.17x

3-Month Avg Trading Volume0.24M

52-Week Price Return-34.39%

Revenue / Employee (TTM)$45,400

Tangible BV / Share (Quarterly)$3.48

P/S Ratio (Annual)38.38x

Asset Turnover (Annual)0.02x

52-Week High$1.96

Operating Margin (5Y Avg)-6431.85%

EPS Excl Extra (Annual)$-0.62

CapEx CAGR (5Y)63.54%

Tangible BV CAGR (5Y)-9.69%

26-Week Price Return70.24%

Quick Ratio (Annual)12.11x

13-Week Price Return12.64%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)20.86x

Enterprise Value$-2.75M

Revenue / Share Growth (5Y)-74.21%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-44.36%

Revenue / Employee (Annual)$57,000

Pretax Margin (Annual)-4689.82%

Cash / Share (Annual)$0.72

3-Month Return Std Dev28.30%

Net Income / Employee (TTM)$-2,145,700

ROE (Last FY)-95.38%

Net Interest Coverage (Annual)-8.77x

EPS Basic Excl Extra (Annual)$-0.62

Receivables Turnover (TTM)0.90x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.50

Receivables Turnover (Annual)0.12x

ROI (TTM)-69.57%

P/S Ratio (TTM)48.19x

Pretax Margin (5Y Avg)-6215.80%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$9.73

Price vs S&P 500 (52W)-58.76%

Year-to-Date Return13.10%

5-Day Price Return-3.91%

EPS Normalized (Annual)$-0.62

ROA (5Y Avg)-68.56%

Net Profit Margin (Annual)-4646.14%

Month-to-Date Return-3.78%

Cash Flow / Share (TTM)$-9.09

EBITD / Share (Annual)$-0.70

Operating Margin (Annual)-5219.12%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-85.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.50

P/TBV (Quarterly)4.86x

P/B Ratio (Annual)0.70x

Inventory Turnover (TTM)0.21x

Pretax Margin (TTM)-4782.82%

Book Value / Share (Annual)$0.83

Price vs S&P 500 (13W)4.38%

Beta2.03x

Revenue / Share (TTM)$0.01

ROE (TTM)-69.57%

52-Week Low$0.28

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.08est. -0.18

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.90

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VYNEVYNE Therapeutics Inc. Common Stock	—	F	C	$0.66
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

VYNE Therapeutics is a biopharmaceutical company developing therapies for immuno-inflammatory skin conditions. The company markets dermatology products AMZEEQ and ZILXI while advancing FMX114 as its lead pipeline candidate for atopic dermatitis treatment. VYNE also maintains pre-clinical programs targeting BET inhibitors for potential future applications.